1. Data & Insights

No More Delays: Accelerating Therapy Starts by Embedding Hub Services in Provider Workflows

Written by Posted on Less than 0 min read

Today’s guest post comes from Shabbir Ahmed, Chief Commercial Officer at CareMetx.

Shabbir explains the barriers that providers face when dealing with branded portals for multiple products. He then maintains that patients can access new therapies more quickly when the manufacturer relies on a brand-agnostic hub connected to a large network of providers and integrated with the systems those providers use daily.

To learn more, download CareMetx’s new 2024 Patient Services Report: Revealing Manufacturer Priorities: Patients Naturally Take Center Stage.

Read on for Shabbir’s insights.

Read more »

© 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.

       
View Original Article
Post Views: 213
Member since
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/
Do you like Drug Channels's articles? Follow on social!

More from Drug Channels

  1. Media & Marketing

Reflections and Photos from the Inaugural Drug Channels Leadership Forum 2025

Wow! What an absolutely incredible time at the inaugural Drug Channels Leadership Forum (DCLF)! Paula and I are beyond grateful to everyone who took the stage to share their insights and to all who participated in making this event so impactful. (Even Paula got on the main stage!) The event was packed with thought-provoking discussions, […]
3 min read
0
  1. Data & Insights

The New Playbook for Patient Support Programs: Flexibility, Focus, and Forward-Thinking

Today’s guest post comes from Josh Marsh, Vice President and General Manager, Sonexus™ Access and Patient Support at Cardinal Health. Josh discusses how patient support programs are evolving, including the shift toward outsourcing individualized hub functions. He lists five characteristics pharmaceutical companies should look for when evaluating outsourced support for long-term program success. To learn […]
2 min read
0
  1. Trends & External Forces

Latest CMS Data Reveal Six Trends Reshaping U.S. Drug Spending

The boffins at the Centers for Medicare & Medicaid Services (CMS) recently dropped the latest National Health Expenditure (NHE) data, which track all U.S. spending on healthcare. (Links below.) We spent an astounding $5,278,588,000,000 on healthcare in 2024. Yes, that’s $5.3 trillion! Retail outpatient prescription drugs accounted for less than 9% of that total. More […]
2 min read
0
  1. Trends & External Forces

Pharma’s Direct-to-Consumer Future Runs Through GoodRx

Today’s guest post is from Laura Jensen, Chief Commercial Officer and President of Pharma Solutions at GoodRx. Laura shares her perspective on how direct-to-consumer (DTC) strategies are evolving and the role that platforms like GoodRx can play in improving access. Click here to learn more about GoodRx’s DTC solution for pharmaceutical manufacturers.  Read on for […]
2 min read
0
  1. Shopper & Customer

Direct-to-Consumer Models: Why They’re Expanding and Where They Deliver the Most Impact

Today’s guest post comes from Jordan Armstrong, Vice President of Business Development at AssistRx. Jordan discusses the uptick in direct-to-consumer (DTC) models for life sciences organizations looking to navigate market challenges and improve patient access. He goes on to describe some potential risks and complexities associated with these models. To learn about AssistRx’s technology solutions […]
2 min read
0
  1. Media & Marketing

Drug Channels News Roundup, October 2025: Vertical Integration Woes, AFPs Gone Wild, Part D’s Decline, 340Bloat, and Dr. G’s ACIP Haunting

Eeek! It’s time for the Drug Channels Halloween roundup of terrifying tales from the dark corners of the healthcare system. Gather your favorite demon hunters and help maintain the Honmoon. This month’s tricks and treats include: Vampiric! How vertically integrated insurers can drain the lifeblood from the U.S. healthcare system Boo! Chilling stories of the shady […]
2 min read
0
  1. Owned Brands (Private Label)

The Stelara Biosimilar Price War: How PBM-Affiliated Private Labels Are Reshaping the Market

The 2025 launch of biosimilars to Johnson & Johnson’s Stelara (ustekinumab) marks another turning point in pharmacy benefit dynamics. But unlike the chaotic rollout of Humira biosimilars, pharmacy benefit managers (PBMs) came prepared. Private label strategies, aggressive pricing, and exclusive formulary deals have transformed what might have been a slow-crawling biosimilar introduction into a full-on […]
2 min read
0
  1. Data & Insights

Starting with the End in Mind: How Pharma Can Build a Smarter Path to Commercialization

Today’s guest post comes from Sean Wagner, VP of Client Partnerships and Carolyn Zele, Advisor, Solution Consulting at MMIT. Sean and Carolyn argue that planning for a successful drug launch must begin early—often well before Phase III. In this article, they present a six-step framework to help manufacturers align clinical development with payer expectations, patient […]
2 min read
0
  1. Media & Marketing

Gross-to-Net Bubble Hits $356B in 2024—But Growth Slows to 10-Year Low

Is the gross-to-net bubble—the ever-widening gap between brand-name drug sales at list prices and their net revenues after rebates and discounts—finally beginning to deflate? Drug Channels Institute (DCI) estimates that the gross-to-net reductions for all brand-name drugs reached $356 billion in 2024, a 7% increase over the previous year. Yet despite this record total, the […]
2 min read
0
  1. Trends & External Forces

Drug Channels News Roundup, November 2024: Employers & Their PBMs, Medicaid vs. 340B, U.S. Drug Prices, and Dr. G Shops for Health Plans

Happy Thanksgiving, everyone! Before you stretch your stomach, stretch your mind with our extra-stuffed helping of food for thought. In this issue: Intriguing data on how employers oversee their PBMs State Medicaid programs carve out PBMs—and get a 340B windfall Are U.S. drug prices really higher than other countries? Plus, Dr. Glaucomflecken gets us ready […]
2 min read
0
  1. Data & Insights

From Integration to AI: The Data-Driven Future of Market Access

Today’s guest post comes from Kala Bala, SVP, Enterprise Access & Data Expertise, MMIT, a Norstella company and Dinesh Kabaleeswaran, SVP, Advisory Services at MMIT, a Norstella company. The authors outline the challenges that manufacturers face when integrating internal and external datasets to build market access and commercialization strategies. They argue that unified datasets and […]
2 min read
0
  1. Media & Marketing

The Top 15 Specialty Pharmacies of 2024: How PBMs, Health Systems, and Independents Are Shaping the Market

Drug Channels Institute’s (DCI’s) latest analysis reveals that PBM-affiliated specialty pharmacies continue to dominate the dispensing of specialty drugs. DCI has identified nearly 1,900 dispensing locations with specialty pharmacy accreditation. Below, we share DCI’s latest analysis of the top 15 specialty pharmacies, including updated market shares and revenue estimates. As in prior years, pharmacies linked […]
2 min read
0
  1. Data & Insights

The Pivotal Role of Technology in Delivering Effective Patient Services

Today’s guest post comes from George Moore, Chief Information Technology Officer at CareMetx. As George explains using novel survey data, manufacturers view new technologies  as crucial for patient services. He then explains how digital technology, artificial intelligence (AI), and machine learning (ML) can be used to improve patient adherence and increase hub efficiencies. To learn […]
2 min read
0
  1. Trends & External Forces

Large Chains’ Position in 2025’s Part D Pharmacy Networks: Supermarkets Take the Lead in a Shrinking PDP Market

In Medicare Part D in 2025: Preferred Pharmacy Networks Fade in a Collapsing PDP Market, I documented the Inflation Reduction Act’s (IRA) disruption to Medicare Part D prescription drug plans (PDPs). Today, we examine the seven largest retail chains’ participation in the 12 major 2025 Part D networks that the five largest plan sponsors will […]
3 min read
0
  1. Trends & External Forces

Who Will Pay for Prescription Drugs in 2032: Four Takeaways from the New Government Forecasts (rerun)

This week, I’m rerunning some popular posts while I prepare for today’s Drug Channels Outlook 2025 live video webinar. (If you sign up before 12 p.m. ET, you can attend the live event.) Click here to see the original post. The econowonks at the Centers for Medicare & Medicaid Services (CMS) recently released the latest […]
2 min read
0
  1. Channel: Drug

Follow the 340B Dollar: Senator Cassidy Exposes How CVS Health and Walgreens Profit as 340B Contract Pharmacies

Two weeks ago, Senator Bill Cassidy—now chair of the Senate Committee on Health, Education, Labor, and Pensions (HELP)—dropped a must-read, eyebrow-raising report on the out-of-control 340B Drug Pricing Program. (Link below.) The report reveals previously confidential information showing how billions are funneled to health systems and pharmacies—with manufacturers unable to follow the flow. Below, we […]
2 min read
0
  1. Media & Marketing

How the IRA’s Part B Coinsurance Inflation Adjustments Can Raise Seniors’ Drug Costs

The Inflation Reduction Act (IRA) is triggering increases in Medicare beneficiaries’ spending on their Part B drugs. Though CMS touts that the IRA’s inflation-based coinsurance adjustments will “lower out-of-pocket costs,” the results have been more complicated. Below, we update and expand on our previous analysis. We find that a growing number of Part B drugs […]
3 min read
0
  1. Department: HBC

Cigna’s Rebate-Free Pharmacy Model: Three Realities Behind Its Latest Push to Pop the Gross-to-Net Bubble

On Monday, Cigna announced that it would be abandoning traditional manufacturer rebates and moving to a new, “rebate-free” approach—essentially a point-of-sale (POS) rebate model paired with a cost-plus pharmacy reimbursement framework. Here’s the press release. Moving manufacturers’ rebates and discounts to the point of dispensing is a big win for patients, who can share in […]
2 min read
0
  1. Data & Insights

The AI Advantage: When and Where to Apply It in Your Patient Support Program

Today’s guest post comes from William Grambley, Chief Product Officer at AssistRx.   William discusses four specific uses cases for how AI can create efficiencies and improve patient support programs for both healthcare providers and patients. He provides three considerations that life sciences organizations should evaluate when adopting AI in their patient support programs.   To […]
2 min read
0
  1. Data & Insights

Informa Connect’s Trade and Channel Strategies

Informa Connect’s Trade and Channel Strategies December 9-11, 2025 | W Philadelphia Exclusive Offer—Use promo 25DC10 to save 10%* The stakes have never been higher. With seismic shifts in distribution models, health policy and market access strategies, falling behind on critical trends could mean losing your competitive edge. If you’re a trade, channel, market access […]
3 min read
0
Next